Device Firms Struggling With Trial Monitoring Could Receive BIMO Guidance
This article was originally published in The Gray Sheet
Executive Summary
FDA's Division of Bioresearch Monitoring will convene a June meeting of industry stakeholders to commence development of a best practices guidance for medical device clinical trial monitoring
You may also be interested in...
BIMO Carves Out Special Investigations Branch To Handle Inspection Tip-offs
Creation of a CDRH Bioresearch Monitoring branch for special investigations will free up remaining staff to focus on "core" activities and meet Medical Device User Fee & Modernization Act timeframes, according to program officials
BIMO Carves Out Special Investigations Branch To Handle Inspection Tip-offs
Creation of a CDRH Bioresearch Monitoring branch for special investigations will free up remaining staff to focus on "core" activities and meet Medical Device User Fee & Modernization Act timeframes, according to program officials
ImPrecise Oversight? Cordis Monitoring Gaps Yield Second Warning Letter
J&J Cordis says it is developing more "robust" systems and processes for overseeing clinical studies in response to FDA's warning letter faulting the company for sponsor monitoring lapses in its SAPPHIRE trial